Quanticate, a data-focused global clinical research organization (CRO), chose Comprehend Clinical™to integrate into its future research tools as a key part of its strategy to expand its offerings to meet growing sponsor demand for real-time communications and comprehensive clinical data analytics.
“We are excited to be able to provide our sponsor customers a more user-friendly, cost effective approach that overcomes the limitations of analytics and visualization tools that are costly and cumbersome to implement and integrate with other systems. Our approach will help our customers get to the data they need to answer critical questions,” said Daniel Chapple, chief commercial officer at Quanticate. “Our selection of Comprehend Systems is a fundamental step in our vision to provide our customers with centralized clinical data services that helps them resolve this data access challenge.”
After Quanticate conducted a thorough evaluation of a range of data analytics vendors, Comprehend Clinical was chosen for its easy-to-use web-based platform and ability to seamlessly integrate into existing clinical systems. The Quanticate team also valued how the system allows researchers to easily find answers to their problems and dig into key data with no additional programming or complicated spreadsheets.
“During our evaluation process of visualization and analytics software, it became clear that Comprehend Clinical’s competitive advantage is its ability to pull data from any source and deliver it in a way that makes sense to researchers,” said Michael Whitworth, vice president of centralized clinical data sciences at Quanticate. “Comprehend Clinical will enable our sponsors to not only drill down and solve unique, specific problems in real time, but also provide a higher level view of data to tackle broader operational challenges.”
“As a leading CRO, Quanticate clearly understands the regulatory, clinical and financial pressures sponsors are under and is aggressively implementing the technologies and services that solve the industry’s biggest pain points,” said Rick Morrison, CEO and founder of Comprehend Systems. “Given our shared commitment to improving the way clinical research is conducted, Quanticate’s strategy to integrate our solution makes perfect sense, and we look forward to successes with joint customers in the months ahead.”
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.